Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

The molecule is a copper-binding tripeptide

GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine. Laboratory work has examined collagen synthesis, glycosaminoglycans, matrix metalloproteinases and skin delivery, but each experiment answers a formulation- and system-specific question.

An older multicentre trial evaluated a particular topical GHK-Cu gel as part of standardized care for diabetic neuropathic ulcers. That is human evidence, but it is narrow evidence: a topical product, a defined wound type and a co-intervention protocol.

Evidence should become more specific as a claim becomes more consequential.

Keep cell, topical and injectable evidence in separate columns

A human fibroblast response supports a biological hypothesis, not a clinical claim. A topical wound result can inform that exact formulation and care setting, but it does not establish systemic exposure, injectable safety or a cosmetic outcome.

Concentration also matters. Early fibroblast work reported effects at low concentrations and a biphasic response in related matrix experiments, illustrating why 'more' cannot be inferred to mean 'better'.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

The injectable evidence gap remains material

FDA notes that compounded injectable GHK-Cu may present immunogenicity and peptide-impurity concerns and that human data are limited. Health Canada includes GHK-Cu in its 2026 advisory on unauthorized injectable peptide products.

These records do not establish that an EternaGen material is safe, effective or equivalent to a studied formulation. They show why molecular identity, route and formulation must stay attached to every interpretation.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 23 July 2026.

  1. Maquart et al. GHK-Cu and collagen synthesis in fibroblast cultures. FEBS Lett. 1988. PMID 3169264.
  2. Mulder et al. GHK-Cu gel in diabetic neuropathic ulcers. Wound Repair Regen. 1994. PMID 17147644.
  3. U.S. FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks: GHK-Cu.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.